Brodovy dny 2023
The 10th Educational Symposium of the Czech Society of Nephrology called Brodovy dny took place in Mikulov from 3 to 5 May 2023. There are not many educational events in the field of nephrology and transplantology during the year, therefore a huge number of doctors came to Mikulov. Special guests were professors from Vienna. They were given the opportunity to share their experience with innovative therapies in hemodialysis, peritoneal dialysis as well as immunosuppression and monoclonal therapy in transplantology.
The subtitle of the symposium “Advances in Diagnosis and Treatment in Nephrology” predetermined the topics of the medical and nursing session programs.
Wednesday’s presymposium mainly addressed the topic of patient placement on the waiting list and the associated algorithm of patient investigation, including cardiology. Practice confirms the rise of preemptive inclusion of patients in the waiting list, i.e. inclusion before starting regular dialysis treatment. As a result, transplant centres are breaking records in the number of kidney transplants year after year.
Thursday’s symposium focused on modern renoprotection approaches. A recent topic has been the effective treatment of cardiorenal syndrome.
The Friday morning session of lectures addressed the diagnosis and treatment of primary and secondary nephropathies. There was also a look at the possibility of genetic diagnosis and news from paediatric nephrology. The afternoon session provided valuable information on the possibilities and use of HIF inducers in the treatment of renal anaemia. Furthermore, there were new developments in peritoneal dialysis and apheresis methods, to which more and more departments have recently been reaching out. The symposium ended with a session on infections in nephrology.
From our point of view, MUDr. Hladinova’s lecture on HIF inducers (prolyl hydroxylase inhibitors), presented as a suitable alternative to ESA (erythropoiesis stimulating agents) treatment of anemia, was beneficial. This addressed in detail the advantages of use over conventional drugs stimulating erythropoiesis via the EPO receptor. The view of the treatment of anaemia has changed considerably since the introduction of ESAs into clinical practice, with the safety of treatment being prioritised over normalisation of haemoglobin values. HIF stabilisers act through stimulation of erythropoiesis genes and thus represent a novel mechanism in the treatment of anaemia. In clinical trials, these agents have shown the same efficacy in increasing haemoglobin levels as conventional ESAs and their safety profile is particularly highlighted. In addition, administration leads to reduced i.v. iron consumption in patients. The oral form suggests the advantage of administration to patients in predialysis and peritoneal dialysis. However, they are also approved for administration to haemodialysis patients, especially recommended for those with higher inflammatory parameters and hyporesponsiveness to ESA. In addition to Roxadustat and Daprodustat, others in the HIF stabilizer series are already in the approval process.
Pharma Division
